NephroSant Publishes Real-World Evidence Showing Potential to Improve the Detection of Early Rejection Events with QSant

SAN FRANCISCO, March 3, 2022 /PRNewswire/ -- NephroSant™ a biotechnology company dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys, with a mission to significantly improve global kidney health, announced that the Journal of Clinical Medicine...

Click to view original post